Afficher la notice abrégée

Evaluation of waning of IgG antibody responses after rVSVDeltaG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

dc.rights.licenseopenen_US
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVALAYER, Simon
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALEXANDRE, Marie
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPRAGUE, Melanie
dc.contributor.authorBEAVOGUI, Abdoul Habib
dc.contributor.authorDOUMBIA, Seydou
dc.contributor.authorKIEH, Mark
dc.contributor.authorGREENWOOD, Brian
dc.contributor.authorLEIGH, Bailah
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPOUPELIN, Marie
dc.contributor.authorSCHWIMMER, Christine
dc.contributor.authorSOW, Samba O
dc.contributor.authorBERRY, Irina Maljkovic
dc.contributor.authorKUHN, Jens H
dc.contributor.authorFUSCO, Daniela
dc.contributor.authorCAUWELAERT, Natasha Dubois
dc.contributor.authorWATSON-JONES, Deborah
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorLEVY, Yves
dc.contributor.authorYAZDANPANAH, Yazdan
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLHOMME, Edouard
dc.date.accessioned2024-12-19T09:20:34Z
dc.date.available2024-12-19T09:20:34Z
dc.date.issued2024-12-01
dc.identifier.issn2222-1751en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/204001
dc.description.abstractEnrVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP(1,2)) antibody concentrations after rVSVΔG-ZEBOV-GP or Ad26.ZEBOV, MVA-BN-Filo vaccination with linear mixed-effect regression models.After a post-vaccination peak, each vaccination strategy was associated with a decrease of anti-EBOV GP(1,2) antibody concentrations with distinct kinetics, highlighting a less-rapid decline in antibody levels after vaccination by rVSVΔG-ZEBOV-GP. One year after administration of the vaccine, antibody concentrations were higher in children compared to adults for both vaccines, although with different effect sizes: 1.74-fold higher concentrations (95% confidence interval [CI] [1.48; 2.02]) for children 12-17 years old to 3.10-fold higher concentrations (95% CI [2.58; 3.69]) for those 1-4 years old compared to adults for Ad26.ZEBOV, MVA-BN-Filo versus 1.36-fold (95% CI [1.12; 1.61]) to 1.41-fold (95% CI [1.21; 1.62]) higher at month 12 higher than these values for adults, with relatively small changes from one age category of children to another for rVSVΔG-ZEBOV-GP. Antibody concentrations also differed according to geographical location, pre-vaccination antibody concentration, and sex.In combination with knowledge on memory response, characterization of the major determinants of immune response durability of both vaccinations may guide future EVD control protocols.Trial registration: ClinicalTrials.gov identifier: NCT02876328..
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enEbola Virus Disease
dc.subject.enWestern Africa
dc.subject.enAntibody
dc.subject.enImmunogenicity
dc.subject.enModelling
dc.subject.enVaccine
dc.title.enEvaluation of waning of IgG antibody responses after rVSVDeltaG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial
dc.title.alternativeEmerg Microbes Infecten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/22221751.2024.2432353en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39559990en_US
bordeaux.journalEmerging microbes & infectionsen_US
bordeaux.page2432353en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDNational Institutes of Healthen_US
bordeaux.identifier.funderIDLondon School of Hygiene and Tropical Medicineen_US
hal.description.error<?xml version="1.0" encoding="utf-8"?> <sword:error xmlns:sword="http://purl.org/net/sword/error/" xmlns="http://www.w3.org/2005/Atom" href="http://purl.org/net/sword/error/ErrorBadRequest"> <title>ERROR</title> <updated>2024-12-20T01:04:37+01:00</updated> <author> <name>HAL SWORD API Server</name> </author> <source> <generator uri="https://api.archives-ouvertes.fr/sword" version="1.0">hal@ccsd.cnrs.fr</generator> </source> <summary>Some parameters sent with the request were not understood</summary> <sword:treatment>processing failed</sword:treatment> <sword:verboseDescription>{"duplicate-entry":{"hal-04817450":{"doi":"1.0"}}}</sword:verboseDescription> <link rel="alternate" href="https://api.archives-ouvertes.fr" type="text/html"/> </sword:error>
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Emerging%20microbes%20&%20infections&amp;rft.date=2024-12-01&amp;rft.volume=14&amp;rft.issue=1&amp;rft.spage=2432353&amp;rft.epage=2432353&amp;rft.eissn=2222-1751&amp;rft.issn=2222-1751&amp;rft.au=VALAYER,%20Simon&amp;ALEXANDRE,%20Marie&amp;PRAGUE,%20Melanie&amp;BEAVOGUI,%20Abdoul%20Habib&amp;DOUMBIA,%20Seydou&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_TEMI_2025_Valayer.pdf
Taille:
555.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
920octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée